AstraZeneca's Zactima "will earn 5% of NSCLC patients by 2016"
Anglo-Swedish drug major AstraZeneca's developmental drug Zactima (vandetanib) will earn a 4.7% patient share in the treatment of non-small cell lung cancer by 2016, according to a new study from health care advisory firm Decision Resources.
Surveyed oncologists indicated that they would prescribe Zactima for 30% of their patients with advanced NSCLC. Also, 38% of the physicians questioned indicated that they will use this drug as an adjunct to current therapy rather than as a replacement. Zactima is projected to be launched in the USA and Europe during the current year and in 2010 in Japan.
Emerging therapies not expected to match current gold-standard regimes
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze